TIGIT and cancer: Based on the number of new trials started in recent years [84], emerging therapies of interest for the future may lie in combinations with approved therapies such as PARP inhibitors, as well as rising IO targets and agents such as TIGIT, TGFβ/TGFR, TLRs, oncolytic viruses, and cancer vaccines.